Nicholas Wealth LLC. Buys 2,337 Shares of AbbVie Inc. $ABBV

Nicholas Wealth LLC. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 20.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 14,034 shares of the company’s stock after buying an additional 2,337 shares during the quarter. AbbVie makes up about 1.3% of Nicholas Wealth LLC.’s portfolio, making the stock its 13th largest position. Nicholas Wealth LLC.’s holdings in AbbVie were worth $2,605,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Conning Inc. boosted its position in AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares during the period. Dohj LLC lifted its stake in shares of AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after buying an additional 1,335 shares in the last quarter. First Hawaiian Bank boosted its holdings in AbbVie by 0.8% in the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after buying an additional 60 shares during the period. BankPlus Trust Department boosted its holdings in AbbVie by 3.3% in the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock worth $5,033,000 after buying an additional 855 shares during the period. Finally, North Star Asset Management Inc. grew its stake in AbbVie by 0.5% in the 1st quarter. North Star Asset Management Inc. now owns 161,320 shares of the company’s stock valued at $33,800,000 after buying an additional 756 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Evercore ISI increased their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Hsbc Global Res lowered AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Bank of America lifted their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Price Performance

Shares of AbbVie stock opened at $233.83 on Wednesday. The business’s 50-day moving average price is $225.84 and its 200-day moving average price is $204.57. The firm has a market capitalization of $413.27 billion, a PE ratio of 111.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.